Patent ID: 7358046

Claim:
A method for determining the sensitivity of a patient's cancerous cells to a candidate anti-cancer therapy, comprising: (a) exposing a sample of the patient's cancerous cells to the candidate anti-cancer therapy in vitro, wherein the candidate anti-cancer therapy comprises a G2 checkpoint-abrogating peptidomimetic selected from the group consisting of CBP500 (SEQ ID NO: 25), CBP501 (SEQ ID NO: 26), CBP504 (SEQ ID NO: 29), CBP505 (SEQ ID NO: 30), CBP506 (SEQ ID NO: 31), CBP510 (SEQ ID NO: 32), CBP511 (SEQ ID NO: 33), CBP512 (SEQ ID NO: 34), and CBP603 (SEQ ID NO: 37); (b) measuring the DNA content of each cancerous cell in the sample after exposure to the candidate anti-cancer therapy; and (c) determining the cell cycle distribution of the sample after exposure to the candidate anti-cancer therapy; wherein a change in the cell cycle distribution of the sample after exposure to the candidate anti-cancer therapy indicates sensitivity of the patient's cancerous cells to the therapy.